December 25, 2014 6:43 PM ET

Pharmaceuticals

Company Overview of Modern Biosciences plc

Company Overview

Modern Biosciences plc is a virtual drug development company. The company engages in the in-licensing, project development, and commercialization of its products. It in-licenses late-stage discovery projects from academia and spin out companies. The company is based in London, the United Kingdom.

60 Cannon Street

London,  EC4N 6JP

United Kingdom

Phone:

44 20 7002 1031

Fax:

44 20 7002 1137

Key Executives for Modern Biosciences plc

Chief Executive Officer and Executive Director
Age: 45
Chief Scientific Adviser of Oncology
Age: 70
Chief Scientific Officer and Executive Director
Compensation as of Fiscal Year 2014.

Modern Biosciences plc Key Developments

Modern Biosciences plc Enters into R&D Alliance and Global Option and Licence Agreement with Janssen Biotech, Inc

IP Group plc announced that Modern Biosciences plc has entered into an R&D alliance and global option and licence agreement with Janssen Biotech, Inc. (Janssen) in relation to MBS' novel bone-protective compounds for the treatment of rheumatoid arthritis (RA). The goal of the collaboration, facilitated by the Johnson & Johnson Innovation Centre in London, is to develop new drugs for the treatment of RA. Under the terms of the exclusive agreement, Modern Biosciences will receive an up-front payment and is eligible to receive development, regulatory and commercialisation milestone payments up to a potential total of £176 million. In addition, MBS will receive royalties on future sales of any products that may result from the alliance upon successful launch and commercialisation.

Modern Biosciences plc Enters into R&D Alliance and Global Option and Licence Agreement with Janssen Biotech, Inc

IP Group plc noted that Modern Biosciences plc has entered into an R&D alliance and global option and licence agreement with Janssen Biotech Inc. in relation to MBS' novel bone-protective compounds for the treatment of rheumatoid arthritis. The goal of the collaboration, facilitated by the Johnson & Johnson Innovation Centre in London, is to develop new drugs for the treatment of RA. Under the terms of the exclusive agreement, Modern Biosciences will receive an up-front payment and is eligible to receive development, regulatory and commercialisation milestone payments up to a potential total of £176 million. In addition, MBS will receive royalties on future sales of any products that may result from the alliance upon successful launch and commercialisation.

Similar Private Companies By Industry

Company Name Region
BioMoti Limited Europe
Theradex (Europe) Ltd. Europe
Hamsard 3149 Ltd Europe
Delta G Ltd. Europe
Psimei Pharmaceuticals PLC Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Modern Biosciences plc, please visit www.modernbiosciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.